跳至主要内容
临床试验/NCT07162662
NCT07162662招募中不适用

Modulation of Gut Microbiota by Oral Sialic Acid: A Mechanistic Study

Xiaolong Li1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2025年9月10日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
42
试验地点
1
主要终点
Alterations in Gut Microbiota Structure

研究概览

简要总结

This is a single-center prospective cohort study conducted by the Department of General Surgery at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital). The purpose of this study is to explore and clarify the effects of sialic acid intervention on gut microbiota structure, with a focus on the proliferation of pathogens (e.g., Escherichia coli, Klebsiella pneumoniae), and to develop novel prevention and treatment strategies for improving intestinal homeostasis.

详细描述

Background:Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies worldwide, ranking third in incidence and second in mortality among all cancers. Surgical resection remains the primary treatment for CRC, particularly for early- and mid-stage patients, as it effectively removes tumor tissue and prolongs survival. However, postoperative anastomotic healing failure (e.g., anastomotic leakage) is a severe complication of colorectal surgery, with an incidence rate of 5%-20%. Anastomotic leakage not only significantly increases postoperative mortality but also prolongs hospital stays, escalates medical costs, and imposes a heavy burden on both patients and healthcare systems. The pathogenesis of anastomotic leakage is complex, involving factors such as local ischemia, surgical technique, infection, and gut microbiota dysbiosis. In recent years, with advancements in microbiomics research, the role of gut microbiota in anastomotic healing has gained increasing attention.

During malignant transformation, colorectal cancer cells exhibit significantly upregulated expression of sialic acid (SA) on their cell surfaces. Sialic acid, a class of nine-carbon monosaccharides widely distributed on mammalian cell surfaces, participates in cell-cell recognition, immune regulation, and host-microbe interactions. Studies have shown that shed sialic acid from colorectal tumor cells enters the intestinal lumen, serving as a critical nutrient source for gut microbes. Notably, certain pathogens (e.g., Escherichia coli, Klebsiella pneumoniae) can utilize sialic acid as a carbon source to promote their proliferation and colonization. These pathogens may impair anastomotic healing through multiple mechanisms: first, by disrupting the intestinal mucosal barrier and exacerbating local inflammation; second, by inhibiting epithelial cell repair and delaying tissue regeneration; and third, by producing toxins or metabolites that further damage local tissues. Thus, colorectal tumor-derived sialic acid may indirectly increase the risk of postoperative anastomotic healing failure by nourishing specific pathogens.

Although existing research suggests that sialic acid from colorectal tumors influences the gut microenvironment by feeding pathogens, the specific mechanisms underlying its impact on postoperative anastomotic healing remain unclear. This hypothesis requires experimental validation. Our preliminary animal studies have demonstrated that oral administration of sialic acid impairs rectal anastomotic healing in mice by modulating gut microbiota. This finding indicates that sialic acid may affect postoperative anastomotic tissue repair and inflammatory responses by altering gut microbiota structure. However, research on the effects of sialic acid on the human gut microbiota remains limited. Based on this background, the present study aims to characterize the impact of sialic acid on gut microbiota by analyzing fecal samples collected from volunteers following oral sialic acid intervention.

Study Design: This study employs a before-after self-control trial design, recruiting 42 volunteers to take oral sialic acid and collecting fecal samples before and after the intervention. Specifically, the control group specimens were fecal samples collected before oral sialic acid administration, while the experimental group specimens were fecal samples collected after oral sialic acid administration.

Primary Objective:Alterations in Gut Microbiota Structure

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged between 18 and 75 years
  • No history of major diseases, no previous surgical history, and no history of cardiometabolic diseases (such as hypertension, diabetes mellitus, obesity, etc.)
  • No use of drugs that may affect gut microbiota or metabolic function (e.g., antibiotics, probiotics, immunosuppressants, etc.);
  • Voluntarily participate in the study and sign the informed consent form.

排除标准

  • Comorbidities: Complicated with other severe diseases (e.g., immunodeficiency, chronic liver disease, renal insufficiency, malignant tumors, etc.).
  • Recent infections: Registration records indicate a history of severe infections in the recent period (within 3 months) or currently receiving anti-infective treatment.
  • Special populations: Pregnant women, lactating women, or women planning to become pregnant.
  • Poor compliance: Volunteers who are unable to cooperate with the study protocol or follow-up

结局指标

主要结局

Alterations in Gut Microbiota Structure

时间窗: From enrollment to the end of treatment at 2 weeks

Gut microbiota data analysis: Perform sequence analysis and OTU clustering using QIIME2 or Mothur; compare microbial diversity (α-diversity and β-diversity) between the experimental group and control group, as well as changes in the abundance of specific microbiota (e.g., Escherichia coli, Klebsiella pneumoniae); use LEfSe analysis to screen for microbiota with significant changes after sialic acid intervention, and predict changes in microbial functions via PICRUSt

次要结局

未报告次要终点

研究者

发起方
Xiaolong Li
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Xiaolong Li

Investigator

Army Medical University, China

研究点 (1)

Loading locations...

相似试验